| Cas No.: | 1123231-07-1 |
| Chemical Name: | WAY262611; WAY 262611 |
| Synonyms: | WAY262611; WAY 262611 |
| SMILES: | N(C1=NC=CC(C2=CC=C3C(=C2)C=CC=C3)=N1)1CCC(CN)CC1 |
| Formula: | C20H22N4 |
| M.Wt: | 318.42 |
| Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
| Description: | WAY-262611 is a wingless β-Catenin agonist that increases bone formation rate with an EC50 of 0.63 μM in TCF-Luciferase assay. |
| In Vivo: | WAY-262611 has excellent pharmacokinetic properties and shows a dose dependent increase in the trabecular bone formation rate in ovariectomized rats following oral administration. Calvariae from wt mice treated with WAY-262611 shows statistically increased BFR, while similarly treated KO animals are no different from control. This indicates that WAY-262611 is acting via the Wnt β-catenin pathway and most likely through inhibition of Dkk-1[1]. |
| In Vitro: | WAY-262611 has the most potent activity in the primary assay, low kinase inhibition potential, and high solubility[1]. |
MSDS
COA
| LOT NO. | DOWNLOAD |
|
|
|
| 2018-0101 |
|
| 2018-0101 |
|